Poor
Not Aligned
Patient Risk:
High
Summary
The response includes multiple kidney-related safety claims, but the provided FDA label excerpts only support cardiovascular boxed warning and gastrointestinal risk. Kidney damage/renal papillary necrosis, susceptibility in pre-existing kidney disease, and hypertension-related progression are not supported by the supplied label text, making overall alignment poor.
Category Scores
Accurate Statements
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID).
Supported generally by the provided label excerpts referring to NSAIDs and ibuprofen (e.g., GI boxed warning: "NSAIDs, including ibuprofen").
Unsupported Statements
High doses or prolonged use of ibuprofen can increase the risk of kidney damage.
Not supported by the supplied FDA label excerpts (only cardiovascular and GI boxed warnings/sections are provided).
High doses or prolonged use of ibuprofen can worsen kidney function.
Not supported by the supplied FDA label excerpts.
Prolonged use of NSAIDs like ibuprofen can lead to renal papillary necrosis.
Not supported by the supplied FDA label excerpts.
Renal papillary necrosis is a condition where tissue in the inner lining of the kidneys' renal pelvis dies.
Not supported by the supplied FDA label excerpts.
People with pre-existing kidney disease may be more susceptible to NSAID-related kidney damage.
Not supported by the supplied FDA label excerpts.
Long-term ibuprofen use in patients with hypertension may increase the risk of kidney disease progression.
Not supported by the supplied FDA label excerpts.
Contradictions
Important Omissions
No statements in the AI response correspond to the provided boxed warnings內容 about cardiovascular thrombotic events (MI/stroke) and gastrointestinal bleeding/ulceration/perforation and their timing/risk factors.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response makes multiple kidney-related risk claims without support from the supplied FDA label excerpts, while omitting the label-supported boxed warnings provided in the prompt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major safety claims about kidney injury/renal papillary necrosis are not supported by the supplied FDA-approved label excerpts (which cover cardiovascular and gastrointestinal boxed warnings).
Suggested Improvement
Restrict safety statements to those supported by the provided label text (cardiovascular thrombotic events; gastrointestinal bleeding/ulceration/perforation) and avoid unsourced kidney-related claims unless the corresponding label sections are provided.